Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening

Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening

286658

Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening

When given in combination with androgen deprivation therapy or ADT, Erleada (apalutamide) significantly prolonged the lives of men with metastatic hormone-sensitive prostate cancer (mHSPC) — without compromising their quality of life — according to final data from a Phase 3 trial. Findings from the study, called TITAN (NCT02489318), also showed that the combination treatment significantly delayed disease progression or death among trial participants, according to Johnson & Johnson, the therapy’s developer. The combo therapy also…

You must be logged in to read/download the full post.